Montana, V., Verkhratsky, A
Safety study of oral edaravone administered in subjects with ALS
Its Coke Zero for the win
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network Open (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021) Carnitine, National Institutes of Health (2023) Effects of three treatment modalities (diet, myoinositol, or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome, European Review for Medical and Pharmacological Sciences (2019) Who can perform semaglutide treatments?, American Med Spa Association (2023) Using fat-dissolving injections that are not FDA-approved can be harmful, U.S
Key reasons GLP-1s require heightened caution in eating disorder populations include: Appetite suppression that may reinforce restrictive behaviors Rapid or significant weight changes that can increase psychological distress Heightened focus on food intake, body cues, or weight-related outcomes Temporary behavioral changes that may mask symptoms rather than address underlying drivers Eating disorders are multifaceted mental health conditions that cannot be effectively treated through appetite or weight changes alone
